AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Global Precision Medical, Inc., (GBPMF) announced that on December 2, 2003, it entered into an agreement to acquire an exclusive worldwide license from MDMI Technologies, Inc., (MDMI), of Richmond, British Columbia, to apply their proprietary "Thermal Ablation Technology" to augment the company's URO-Stent in the treatment of Benign Prostate Hyperplasia (BPH).
BPH is a noncancerous enlargement of the prostate, which compresses the urethra as it grows, thereby restricting the flow of urine - a primary cause of urinary voiding dysfunction in men. Medical device industry research to bring Thermal Ablation Technology to the treatment of BPH is intensifying, and it is believed that the MDMI technology may be well suited to treat this widespread condition within the aging male population.
Within the framework of a "Consortium Letter of Understanding," MDMI, under a research and development (R&D) agreement, is to provide R&D services to take the Thermablate Technology through to animal trials. ...